BACKGROUND: Preeclampsia is a multisystem disorder of pregnancy, originating in the placenta. Cytochrome P450 (CYP)-dependent eicosanoids regulate vascular function, inflammation, and angiogenesis, which are mechanistically important in preeclampsia. METHODS AND RESULTS: We performed microarray screening of placenta and decidua (maternal placenta) from 25 preeclamptic women and 23 control subjects. The CYP subfamily 2J polypeptide 2 (CYP2J2) was upregulated in preeclamptic placenta and decidua. Reverse-transcription polymerase chain reaction confirmed the upregulation, and immunohistochemistry localized CYP2J2 in trophoblastic villi and deciduas at 12 weeks and term. The CYP2J2 metabolites, 5,6-epoxyeicosatrienoic acid (EET), 14,15-EET, and the corresponding dihydroxyeicosatrienoic acids, were elevated in preeclamptic women compared with controls in the latter two thirds of pregnancy and after delivery. Stimulating a trophoblast-derived cell line with the preeclampsia-associated cytokine tumor necrosis factor-α enhanced CYP2J2 gene and protein expression. In 2 independent rat models of preeclampsia, reduced uterine-perfusion rat and the transgenic angiotensin II rat, we observed elevated EET, dihydroxyeicosatrienoic acid, and preeclamptic features that were ameliorated by the CYP epoxygenase inhibitor N-(methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide (MsPPOH). Uterine arterial rings of these rats also dilated in response to MsPPOH. Furthermore, 5,6-EET could be metabolized to a thromboxane analog. In a bioassay, 5,6-EET increased the beating rate of neonatal cardiomyocytes. Blocking thromboxane synthesis reversed that finding and also normalized large-conductance calcium-activated potassium channel activity. CONCLUSIONS: Our data implicate CYP2J2 in the pathogenesis of preeclampsia and as a potential candidate for the disturbed uteroplacental remodeling, leading to hypertension and endothelial dysfunction.
BACKGROUND: Preeclampsia is a multisystem disorder of pregnancy, originating in the placenta. Cytochrome P450 (CYP)-dependent eicosanoids regulate vascular function, inflammation, and angiogenesis, which are mechanistically important in preeclampsia. METHODS AND RESULTS: We performed microarray screening of placenta and decidua (maternal placenta) from 25 preeclamptic women and 23 control subjects. The CYP subfamily 2J polypeptide 2 (CYP2J2) was upregulated in preeclamptic placenta and decidua. Reverse-transcription polymerase chain reaction confirmed the upregulation, and immunohistochemistry localized CYP2J2 in trophoblastic villi and deciduas at 12 weeks and term. The CYP2J2 metabolites, 5,6-epoxyeicosatrienoic acid (EET), 14,15-EET, and the corresponding dihydroxyeicosatrienoic acids, were elevated in preeclamptic women compared with controls in the latter two thirds of pregnancy and after delivery. Stimulating a trophoblast-derived cell line with the preeclampsia-associated cytokine tumornecrosis factor-α enhanced CYP2J2 gene and protein expression. In 2 independent rat models of preeclampsia, reduced uterine-perfusion rat and the transgenic angiotensin IIrat, we observed elevated EET, dihydroxyeicosatrienoic acid, and preeclamptic features that were ameliorated by the CYP epoxygenase inhibitor N-(methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide (MsPPOH). Uterine arterial rings of these rats also dilated in response to MsPPOH. Furthermore, 5,6-EET could be metabolized to a thromboxane analog. In a bioassay, 5,6-EET increased the beating rate of neonatal cardiomyocytes. Blocking thromboxane synthesis reversed that finding and also normalized large-conductance calcium-activated potassium channel activity. CONCLUSIONS: Our data implicate CYP2J2 in the pathogenesis of preeclampsia and as a potential candidate for the disturbed uteroplacental remodeling, leading to hypertension and endothelial dysfunction.
Authors: Neroli S Sunderland; Sally E Thomson; Scott J Heffernan; Shirlene Lim; John Thompson; Robert Ogle; Paul McKenzie; Paul J Kirwan; Angela Makris; Annemarie Hennessy Journal: Cytokine Date: 2011-07-06 Impact factor: 3.861
Authors: Michael M Yeboah; Md Abdul Hye Khan; Marla A Chesnik; Melissa Skibba; Lauren L Kolb; John D Imig Journal: Nephrol Dial Transplant Date: 2018-08-01 Impact factor: 5.992
Authors: Victor M Pulgar; Liliya M Yamaleyeva; Jasmina Varagic; Carolynne McGee; Michael Bader; Ralf Dechend; K Bridget Brosnihan Journal: Am J Physiol Endocrinol Metab Date: 2015-09-22 Impact factor: 4.310
Authors: Jessica L Faulkner; Nicole L Plenty; Kedra Wallace; Lorena M Amaral; Mark W Cunningham; Sydney Murphy; Babbette LaMarca Journal: Prostaglandins Other Lipid Mediat Date: 2017-09-22 Impact factor: 3.072
Authors: Nancy Freitag; Irene Tirado-González; Gabriela Barrientos; Florian Herse; Victor L J L Thijssen; Susanne M Weedon-Fekjær; Herbert Schulz; Gerd Wallukat; Burghard F Klapp; Tania Nevers; Surendra Sharma; Anne Cathrine Staff; Ralf Dechend; Sandra M Blois Journal: Proc Natl Acad Sci U S A Date: 2013-06-24 Impact factor: 11.205
Authors: Michael R La Frano; Johannes F Fahrmann; Dmitry Grapov; Theresa L Pedersen; John W Newman; Oliver Fiehn; Mark A Underwood; Karen Mestan; Robin H Steinhorn; Stephen Wedgwood Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-08-16 Impact factor: 5.464
Authors: Victor M Pulgar; Liliya M Yamaleyeva; Jasmina Varagic; Carolynne M McGee; Michael Bader; Ralf Dechend; Allyn C Howlett; K Bridget Brosnihan Journal: Hypertension Date: 2014-06-16 Impact factor: 10.190
Authors: Lukasz Przybyl; Nadine Haase; Michaela Golic; Julianna Rugor; Maria Emilia Solano; Petra Clara Arck; Martin Gauster; Berthold Huppertz; Christoph Emontzpohl; Christian Stoppe; Jürgen Bernhagen; Lin Leng; Richard Bucala; Herbert Schulz; Arnd Heuser; M Susanne Weedon-Fekjær; Guro M Johnsen; Dirk Peetz; Friedrich C Luft; Anne Cathrine Staff; Dominik N Müller; Ralf Dechend; Florian Herse Journal: Circ Res Date: 2016-05-19 Impact factor: 17.367
Authors: Ara Askari; Scott J Thomson; Matthew L Edin; Darryl C Zeldin; David Bishop-Bailey Journal: Prostaglandins Other Lipid Mediat Date: 2013-03-06 Impact factor: 3.072